The FALSE Statement is D
Statement D ("There are no vaccines available for the prevention of meningitis") is categorically false. Multiple meningococcal vaccines have been available and recommended for decades, with quadrivalent polysaccharide vaccines protecting against serogroups A, C, Y, and W-135 available since at least 2000, and conjugate vaccines (MenACWY) licensed and routinely recommended for adolescents since 2005 1, 2, 1. Additionally, vaccines against Streptococcus pneumoniae (a leading cause of bacterial meningitis) and Haemophilus influenzae type b have been part of routine immunization schedules for years.
Why the Other Statements Are TRUE
Statement A: Petechial Rash in Meningococcal Meningitis
This is accurate. Meningococcal disease characteristically presents with petechiae or purpura, particularly in cases of meningococcal septicaemia, which occurs in approximately 20% of cases 3. The petechial rash is a critical diagnostic clue that should prompt immediate consideration of meningococcal disease, even in the absence of classic meningitis signs 4.
Statement B: Diagnosis via Lumbar Puncture and CSF Culture
This remains the gold standard for diagnosing bacterial meningitis 5, 6, 7. Cerebrospinal fluid analysis obtained through lumbar puncture is essential because:
- Clinical findings alone are unreliable for definitive diagnosis
- CSF examination provides critical information on cell count, glucose, protein, and bacterial identification
- Culture confirmation guides targeted antimicrobial therapy
Important caveat: In patients with suspected bacterial meningitis who have immunocompromised states, history of CNS disease, new-onset seizures, papilledema, abnormal consciousness, or focal neurologic deficits, CT imaging should precede lumbar puncture 5. However, antibiotics should never be delayed while awaiting imaging or lumbar puncture 3, 6.
Statement C: Kernig's and Brudzinski's Signs
These are indeed characteristic clinical findings of meningitis 3, 8. However, a critical pitfall: these signs have variable sensitivity and specificity and may not reliably differentiate bacterial from aseptic meningitis 7. Their absence does not rule out meningitis, particularly in early presentations or in infants and young children who may display less specific features like poor feeding, irritability, and a full fontanelle 3.
Statement E: Headache, Fever, and Photophobia
These are frequently observed clinical signs. While the classic triad of fever, nuchal rigidity, and altered mental status is taught, up to 95% of patients will have at least two of four cardinal symptoms: fever, nuchal rigidity, altered mental status, and headache 6. Photophobia is commonly associated with meningeal irritation 3.
The Vaccine Evidence
The evidence unequivocally demonstrates vaccine availability:
- Meningococcal polysaccharide vaccines (MPSV4) have been available since at least 2000, protecting against serogroups A, C, Y, and W-135 1, 9
- Meningococcal conjugate vaccines (MenACWY) were licensed in 2005 and became routinely recommended for adolescents aged 11-18 years by 2007 2, 1
- Conjugate C vaccines were introduced in the UK in 1999 and in the US within 2-4 years thereafter 9
- Current ACIP recommendations include routine adolescent vaccination at age 11-12 years with a booster at age 16 years 2
Note: While serogroup B vaccines were not available in the US as of 2013 2, this does not negate the existence of vaccines for other serogroups that cause the majority of meningococcal disease in persons aged >11 years (75% caused by serogroups C, Y, or W-135) 1.